Allergies News and Research

Latest Allergies News and Research

NAC to deliver education program on asthma management for youth

As children with asthma head back to school this fall, the National Asthma Campaign Foundation (NAC) is partnering with Respiratory Health Association of Metropolitan Chicago (RHAMC) to deliver Fight Asthma Now (FAN), an asthma education program that teaches youth to control and manage their asthma.

13 Aug 2010

Clearstone Central Laboratories announces strategic global collaboration with LabCorp

Clearstone Central Laboratories, a leading provider of central laboratory services for late-stage clinical trials, announced today a global collaboration with Laboratory Corporation of America® Holdings through its Esoterix Clinical Trials Services division, providing clients with seamless access to CAP-accredited laboratories across both organizations in Belgium, Canada, China, France, Singapore and the United States.

13 Aug 2010

Human Immune Phenotyping Centers to receive NIAID grants for research

A new nationwide research initiative has been launched to define changes in the human immune system, using human and not animal studies, in response to infection or to vaccination. Six U. S.-based Human Immune Phenotyping Centers will receive a total of $100 million over five years to conduct this research.Funding for the centers is provided by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Support for the first year of this initiative will come from the American Recovery and Reinvestment Act.

12 Aug 2010

Einstein College receives grant to develop stem cell-based therapies

Scientists at Albert Einstein College of Medicine of Yeshiva University have received a five-year, $10.8 million grant to develop stem cell-based therapies that could be used to mitigate radiation-induced gastrointestinal syndrome - part of acute radiation syndrome (ARS) - for military personnel, first responders and the general public. The Einstein research, funded by the federal Centers for Medical Countermeasures Against Radiation, is part of a program coordinated by the National Institute of Allergy and Infectious Diseases.

12 Aug 2010

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients

OptiNose Inc. announced today that a subgroup analysis of positive Phase II trial results has been published in the July/August issue of the American Journal of Rhinology & Allergy.

11 Aug 2010

Tamir Biotechnology's three compounds effective show potential for yellow fever

Tamir Biotechnology, Inc.(formerly Alfacell Corporation) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of three of our company's compounds showed in vitro results rarely seen before by the U.S. government for yellow fever.

11 Aug 2010

NIAID launches clinical trials of dengue vaccine

After more than a decade of development, the National Institute of Allergy and Infectious Diseases (NIAID) has started clinical trials to test a vaccine to protect against the dengue virus, a product researchers hope may one day "help prevent a disease to which 2.5 billion people are exposed," CIDRAP News reports (Roos, 8/9).

11 Aug 2010

NIH begins human clinical testing for dengue virus vaccine

After more than a decade of development at the National Institutes of Health, a vaccine to prevent infection by the mosquito-borne dengue virus has begun human clinical testing. The vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and is undergoing clinical study at the Johns Hopkins Bloomberg School of Public Health in Baltimore.

10 Aug 2010

Athersys second-quarter revenues increase to $1.9 million

Athersys, Inc. today announced its financial results for the quarter ended June 30, 2010.

10 Aug 2010

Allergy shots can cause systemic side effects: Study

Allergy shots can reduce symptoms of asthma, use of inhaled medications and allergy-related asthma attacks, confirms an updated review of studies. Yet, the treatment can also cause systemic side effects that range from a stuffy nose to fatal anaphylactic shock.About 30 percent of asthma patients experience improved breathing after receiving a series of injections that desensitize their immune systems to specific irritants, according to the review. The medical term for this treatment protocol is allergen immunotherapy.

9 Aug 2010

Chicago's mold count increases to 49,789, says allergist

Chicago's mold count is 49,789 - just a few spores away from the 50,000 threshold that signals a dangerous air quality warning. Today's mold count is the highest of the season, and the highest in five years. "Headaches, sinus congestion, runny noses and fatigue will be common among Chicagoans," says Dr Joseph Leija, allergist at Loyola's Gottlieb Memorial Hospital

7 Aug 2010

Multiple tattoos increase risk of contracting hepatitis C: Study

Youth, prison inmates and individuals with multiple tattoos that cover large parts of their bodies are at higher risk of contracting hepatitis C and other blood-borne diseases, according to a University of British Columbia study.The researchers reviewed and analysed 124 studies from 30 countries, including Canada, Iran, Italy, Brazil and the United States, and found the incidence of hepatitis C after tattooing is directly linked with the number of tattoos an individual receives. The findings are published in the current issue of the International Journal of Infectious Diseases.

7 Aug 2010

ViroPharma announces data on safety, efficacy of Cinryze to treat acute angioedema attacks

ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.

6 Aug 2010

Dyax announces first Phase 3 trial results of KALBITOR for acute HAE

Dyax Corp. announced today that results from EDEMA3, the Company's first Phase 3 trial evaluating KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema, were published in the August issue of The New England Journal of Medicine. KALBITOR, discovered and developed by Dyax, is available in the United States for the treatment of acute attacks of HAE in patients 16 years of age and older.

6 Aug 2010

Dermatologist discusses treatment for acne and melasma

The U.S. Census Bureau predicts that the Asian-American population will total 40 million people by 2050. While as a whole this group is characterized by very dark hair and dark eyes, there is much diversity in Asian skin tones – from very light, pale skin to light or dark brown skin. One common thread is the pigmentation issues that Asian Americans often face as after-effects of other dermatologic problems that can be as troublesome as the original condition itself.

6 Aug 2010

Cobalis, BESPHarma partner to launch national distribution program for PreHistin Allergy Defense Formula

Cobalis Corp. announced today that it has entered into a 5-year distribution partnership agreement with Florida-based BESPHarma, LLC to launch a national distribution program wherein physicians and healthcare providers can offer their patients PreHistin Allergy Defense Formula directly in their offices.

6 Aug 2010

Hayfever: time we moved exams to the winter?

Crucial exams take place during adolescence in most societies, which can have a major impact on an individual’s career trajectory. In a Guest Editorial appearing in the August issue of Expert Review of Respiratory Medicine, a team of UK experts review the evidence of the disease burden associated with hayfever and summarize recent evidence suggesting that poorly controlled hayfever can adversely impact on exam performance.

5 Aug 2010

Infinity reports $18.4 million total revenue for second-quarter 2010

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today detailed recent developments in its product development portfolio and announced second quarter 2010 financial results.

4 Aug 2010

Matrixx Initiatives first-quarter net loss reduces to $2.4 million

Matrixx Initiatives, Inc., an over-the-counter healthcare company that develops and markets Zicam® products, today announced financial results for its fiscal first quarter ended June 30, 2010.

4 Aug 2010